bepafant has been researched along with Bright Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Freudenberg, J; Jocks, T; Stahl, RA; Zahner, G | 1 |
| Brecht, HM; Helmchen, UM; Oberle, G; Schoeppe, W; Stahl, RA; Thaiss, F; Wenzel, U | 1 |
| Neugarten, J; Schlondorff, D; Yoo, J | 1 |
3 other study(ies) available for bepafant and Bright Disease
| Article | Year |
|---|---|
Platelet-activating factor mediates monocyte chemoattractant protein-1 expression in glomerular immune injury.
Topics: Animals; Azepines; Chemokine CCL2; Complement System Proteins; Glomerulonephritis; Kidney Glomerulus; Male; Platelet Activating Factor; Polymerase Chain Reaction; Rabbits; Rats; Rats, Wistar; RNA, Messenger; Triazoles | 1998 |
The platelet activating factor receptor antagonist WEB 2170 improves glomerular hemodynamics and morphology in a proliferative model of mesangial cell injury.
Topics: Animals; Antilymphocyte Serum; Azepines; Dinoprostone; Disease Models, Animal; Glomerular Filtration Rate; Glomerular Mesangium; Glomerulonephritis; Inulin; Male; Platelet Membrane Glycoproteins; Rats; Rats, Inbred Strains; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Thromboxane B2; Triazoles | 1991 |
Protective effects of specific platelet-activating factor receptor antagonists in experimental glomerulonephritis.
Topics: Animals; Azepines; Glomerular Filtration Rate; Glomerulonephritis; Hemodynamics; Kidney; Male; Platelet Activating Factor; Rats; Rats, Inbred Strains; Triazoles | 1991 |